HC Wainwright & Co. Maintains Buy on Pliant Therapeutics, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Pliant Therapeutics (NASDAQ:PLRX) and raised the price target from $36 to $38.
August 12, 2024 | 9:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Pliant Therapeutics and raised the price target from $36 to $38.
The Buy rating and increased price target from a reputable analyst firm like HC Wainwright & Co. is likely to positively impact investor sentiment and drive short-term price appreciation for PLRX.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100